Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.
Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia.
VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States
Hope Clinic of the Emory Vaccine Center, Decatur, Georgia, United States
Mental Health Center Copenhagen, Bispebjerg, Copenhagen N, Denmark
UW Family Medicine Residency Clinics, Madison, Wisconsin, United States
Temple University Episcopal Hospital, Philadelphia, Pennsylvania, United States
Laureate Institute for Brain Research, Tulsa, Oklahoma, United States
Children's Hospital Los Angeles, Los Angeles, California, United States
Children's Hospital Colorado, Aurora, Colorado, United States
Shanghai Mental Health Center, Shanghai, China
Toronto Western Hospital, Toronto, Ontario, Canada
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.